Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. - Wikidata - wikimedia - TriplyDB

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

http://www.wikidata.org/entity/Q37247660

about

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams Integrated therapy for HIV and tuberculosis Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections Novel therapeutic strategies targeting HIV integrase Long-term efficacy and safety of raltegravir in the management of HIV infection.Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis HIV and Tuberculosis: a Deadly Human Syndemic Getting to 90-90-90 in paediatric HIV: What is needed?Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data.Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy Update on opportunistic infections in the era of effective antiretroviral therapy Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.Role of raltegravir in the management of HIV-1 infection.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.TB and HIV Therapeutics: Pharmacology Research Priorities.The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics Drug-drug interactions with raltegravir The use of integrase inhibitors in treatment-experienced patients.Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.Novel integrase inhibitors for HIV.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.Role of raltegravir in HIV-1 management.Pharmacology of HIV integrase inhibitors.Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons.Raltegravir as antiretroviral therapy in HIV/AIDS.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Drug metabolism and drug interactions: potential application to antituberculosis drugs.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.The challenges of pharmacokinetic variability of first-line anti-TB drugs.

P2860

Q24631021-050C3EBD-2706-4F4A-8B8A-9531114AB43C Q26749428-512EC857-C7AF-4E69-8A4C-649106B64613 Q26774267-3D97218E-9EA7-4A6B-A9EE-3DD6196A5CF6 Q26781386-66865F41-1B5C-4ED3-91B9-8501A080612F Q27003960-D23DA353-4C02-446C-B8BC-7B7EC91948A5 Q27686870-3385A264-351B-4723-A5F2-7CE918C9534F Q28069032-4F7133A7-DFE2-48D3-80E5-0BD6FAE20F48 Q30052157-FB43ECA3-AA7B-46F8-BF00-AA5D9A38E14B Q30385352-43CCBAA0-8F5E-4A88-8C00-5ADBD9FA1F3A Q30884873-3CFBDD02-AA10-48DF-954B-65340631FE52 Q33554432-D9510933-5AD7-4FF6-8A10-C4B1AA32B251 Q33585344-D79F6DE6-79E8-4B06-970A-3A6F55C8E32B Q33644204-94704B26-D3AB-42A2-B0F6-89BD13BF2041 Q34085853-89820EBF-8E12-4C91-8A61-B7CEA9B19F1F Q34455442-96D42C8E-D31D-499D-9A14-05CF72084440 Q34529127-08F8CE3C-4C6E-4FA9-A9A3-FB893D193846 Q35026582-EFC62210-54F7-464E-AFF4-251BF7E39AC7 Q35026604-392332AC-24F6-4B3E-AAEF-B91485ADE94E Q35557318-7974162E-EDD6-475D-9A0B-944A24879D7E Q35789343-1251007E-247C-4B5E-94C0-6464E43663BE Q36099838-90134134-ED56-4EAF-BBE5-E8B76ACD4FE1 Q36475104-1AEC4134-DFB8-4E3D-9F9A-2B27931CAF36 Q37180338-31D53D9C-D38B-4B75-9CDF-93585B27D5EA Q37551700-5908D6A0-89F1-4324-A0D3-662428B85C87 Q37644118-D2FA19E3-5C7C-4F03-9EA9-A06D5AF3DF04 Q37644122-400E87C7-A0F1-4E5B-BB7F-C05392632EAA Q37779319-A691F93B-B24F-4663-BBE7-10CBB59C7A05 Q37779774-DC6BD63D-EA52-4D6A-A611-B52524558487 Q37826300-6B6A6374-FC2B-4AEA-8098-3743C911BD26 Q37845854-ED90F83E-DFA9-4BDE-94D8-BC1F762BA856 Q37857334-587949C4-7E24-4035-899A-748852ADE01F Q38002011-F22F529E-BE3E-402F-8BA8-61632FA1B5D5 Q38025835-8168C6E2-B047-402F-A46B-5D361918962F Q38107500-0F5B6E6B-78DE-4FAE-8DFE-F64201D1C4E5 Q38168587-F707F99C-012F-4170-9DE3-0BF4E34CF163 Q38207924-9840C8D9-5B53-4C4E-9440-B4616559454B Q38502286-928C6DA8-7A71-41C2-95BD-F43844E4E552 Q38560855-D87544B5-1E80-48E0-8029-3FD58AD26932 Q38874266-B2F0D988-41B3-456F-A436-8E4F8FDDEEFB Q38977166-73F10A48-4A6F-4F6A-89A8-84007F3F5005

P2860

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

http://www.wikidata.org/entity/Q37247660

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@en

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@nl

type

label

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@en

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@nl

prefLabel

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@en

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@nl

P1433

Q37247660-EA71B129-AC78-42A6-9A10-89F0AE3FAAD5

P1476

Q37247660-77794FFA-F0C0-4583-8C20-4B1D2C4C2124

P2093

Q37247660-0D865E29-4005-4D75-867D-A9B855D4852F

Q37247660-0EC504ED-59AD-44D2-A8A6-93248B6569A6

Q37247660-2AE801B3-50D6-4575-AA53-0B1B4F2C31C1

Q37247660-2FD7CA36-EBAA-483C-8CBE-FA196A4E1F61

Q37247660-3AECAAFB-8E90-4460-AD8C-5D3DD80CA0ED

Q37247660-5DA09FC8-2711-4D66-BD0A-84EEB9C7BEB8

Q37247660-6AE73B6C-4824-4D26-BBD9-AF60F9B76344

Q37247660-920EF0DB-5684-47F6-8A59-147CFE7D9FE0

Q37247660-E0F09E3A-94BC-40B6-A267-7CF4C5F81DE6

Q37247660-E70A682E-8344-4FC0-81BB-8F446493C769

P2860

Q37247660-07D5BF85-F3DC-4A56-8190-E054E8933332

Q37247660-0E85E1CB-B3CE-44AC-94CB-1F6B1CD92E22

Q37247660-17FFFF96-A43A-44EC-AD3F-31F8080A7220

Q37247660-59563814-A2EE-44F3-96B3-802C79CB8147

Q37247660-7382BED6-2BE2-45ED-A0B9-9C08B65593AB

Q37247660-7C8A3109-48CA-4B62-BE91-53A761F29AD5

Q37247660-A65E18F9-B2F7-49E1-AE04-7CA6BB9BA0B8

Q37247660-B0057875-E6C9-4718-A60B-24BB6A9457C7

Q37247660-BC5FA748-AAA2-492C-A0BF-0D764C119E50

Q37247660-CB74867F-D651-4510-BCC3-287BA1DEB0A2

P304

Q37247660-3A99451D-E50C-4D46-A09D-5B03D3415701

P31

Q37247660-858EC1EE-FDB1-4FC2-8823-437479F98F52

P356

Q37247660-A6262789-127E-4485-8B1A-213ACF4903A0

P407

Q37247660-3C8F5B1D-B7CF-4AB9-B75A-26C12864D230

P433

Q37247660-217B09B0-B52A-4E3C-9156-37FFAC0AE305

P478

Q37247660-BF081D97-38EA-4CDA-8B21-C5869F15E71A

P577

Q37247660-A4ED33EB-334B-452A-8053-12D4866956D4

P698

Q37247660-8B0FA94A-CC1E-430E-9AB3-8A396895D420

P932

Q37247660-5EF7A176-F112-451E-8F50-2BDEE31A9DDA

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Effect of rifampin, a potent i ...... armacokinetics of raltegravir.

@en

P2093

Amelia S Petry

http://www.w3.org/2001/XMLSchema#string

Bo Jin

http://www.w3.org/2001/XMLSchema#string

Diana M Brainard

http://www.w3.org/2001/XMLSchema#string

Eric Mangin

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Chodakewitz

http://www.w3.org/2001/XMLSchema#string

John A Wagner

http://www.w3.org/2001/XMLSchema#string

Jolene K Berg

http://www.w3.org/2001/XMLSchema#string

Julie A Stone

http://www.w3.org/2001/XMLSchema#string

Kalyan Ghosh

http://www.w3.org/2001/XMLSchema#string

Keith M Gottesdiener

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

HIV integrase structure and function.

HIV-1 integrase: structural organization, conformational changes, and catalysis.

Update on rifampin and rifabutin drug interactions.

Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

P304

2852-2856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01468-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19433563

http://www.w3.org/2001/XMLSchema#string

P932

2704654

http://www.w3.org/2001/XMLSchema#string